BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, Schinazi RF. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology. 2001;33:751-757. [PMID: 11230757 DOI: 10.1053/jhep.2001.22166] [Cited by in Crossref: 287] [Cited by in F6Publishing: 253] [Article Influence: 14.4] [Reference Citation Analysis]
Number Citing Articles
1 Li MW, Hou W, Wo JE, Liu KZ. Character of HBV (hepatitis B virus) polymerase gene rtM204V/I and rtL180M mutation in patients with lamivudine resistance. J Zhejiang Univ Sci B. 2005;6:664-667. [PMID: 15973769 DOI: 10.1631/jzus.2005.b0664] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
2 Bozdayi AM, Uzunalimoğlu O, Türkyilmaz AR, Aslan N, Sezgin O, Sahin T, Bozdayi G, Cinar K, Pai SB, Pai R, Bozkaya H, Karayalçin S, Yurdaydin C, Schinazi RF. YSDD: a novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine. J Viral Hepat 2003;10:256-65. [PMID: 12823591 DOI: 10.1046/j.1365-2893.2003.00435.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 2.2] [Reference Citation Analysis]
3 Yim HJ. [Hepatitis B virus genetic diversity and mutant]. Korean J Hepatol. 2008;14:446-464. [PMID: 19119240 DOI: 10.3350/kjhep.2008.14.4.446] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
4 Wang YX, Luo C, Zhao D, Beck J, Nassal M. Extensive mutagenesis of the conserved box E motif in duck hepatitis B virus P protein reveals multiple functions in replication and a common structure with the primer grip in HIV-1 reverse transcriptase. J Virol 2012;86:6394-407. [PMID: 22514339 DOI: 10.1128/JVI.00011-12] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
5 Di Marco V, Marzano A, Lampertico P, Andreone P, Santantonio T, Almasio PL, Rizzetto M, Craxì A. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology. 2004;40:883-891. [PMID: 15382125 DOI: 10.1002/hep.20381] [Cited by in Crossref: 31] [Cited by in F6Publishing: 69] [Article Influence: 1.8] [Reference Citation Analysis]
6 Tong W, Sun L, He J, He S, Du F. A novel nucleotide insertion in S gene of hepatitis B virus in a chronic carrier. Virol J 2010;7:104. [PMID: 20492719 DOI: 10.1186/1743-422X-7-104] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
7 Chandra PK, Biswas A, Datta S, Banerjee A, Panigrahi R, Chakrabarti S, De BK, Chakravarty R. Subgenotypes of hepatitis B virus genotype D (D1, D2, D3 and D5) in India: differential pattern of mutations, liver injury and occult HBV infection. J Viral Hepat. 2009;16:749-756. [PMID: 19457142 DOI: 10.1111/j.1365-2893.2009.01129.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 3.5] [Reference Citation Analysis]
8 Tillmann HL. Antiviral therapy and resistance with hepatitis B virus infection. World J Gastroenterol. 2007;13:125-140. [PMID: 17206760 DOI: 10.3748/wjg.v13.i1.125] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 50] [Article Influence: 3.6] [Reference Citation Analysis]
9 Hsiao LT, Chiou TJ, Liu JH, Chu CJ, Lin YC, Chao TC, Wang WS, Yen CC, Yang MH, Tzeng CH. Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant. 2006;12:84-94. [PMID: 16399572 DOI: 10.1016/j.bbmt.2005.09.001] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
10 Hayer J, Jadeau F, Deléage G, Kay A, Zoulim F, Combet C. HBVdb: a knowledge database for Hepatitis B Virus. Nucleic Acids Res. 2013;41:D566-D570. [PMID: 23125365 DOI: 10.1093/nar/gks1022] [Cited by in Crossref: 115] [Cited by in F6Publishing: 97] [Article Influence: 12.8] [Reference Citation Analysis]
11 Beloukas A, Geretti AM. Hepatitis B Virus Drug Resistance. In: Mayers DL, Sobel JD, Ouellette M, Kaye KS, Marchaim D, editors. Antimicrobial Drug Resistance. Cham: Springer International Publishing; 2017. pp. 1227-42. [DOI: 10.1007/978-3-319-47266-9_26] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
12 Hong SP, Kim NK, Hwang SG, Chung HJ, Kim S, Han JH, Kim HT, Rim KS, Kang MS, Yoo W. Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments. J Hepatol. 2004;40:837-844. [PMID: 15094233 DOI: 10.1016/j.jhep.2004.01.006] [Cited by in Crossref: 89] [Cited by in F6Publishing: 84] [Article Influence: 5.2] [Reference Citation Analysis]
13 Papatheodoridis GV, Dimou E, Papadimitropoulos V. Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance. Am J Gastroenterol. 2002;97:1618-1628. [PMID: 12135009 DOI: 10.1111/j.1572-0241.2002.05819.x] [Cited by in Crossref: 91] [Cited by in F6Publishing: 73] [Article Influence: 4.8] [Reference Citation Analysis]
14 Umeoka F, Iwasaki Y, Matsumura M, Takaki A, Kobashi H, Tatsukawa M, Shiraha H, Fujioka S, Sakaguchi K, Shiratori Y. Early detection and quantification of lamivudine-resistant hepatitis B virus mutants by fluorescent biprobe hybridization assay in lamivudine-treated patients. J Gastroenterol 2006;41:693-701. [PMID: 16933008 DOI: 10.1007/s00535-006-1834-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
15 Rahimi R, Hosseini SY, Fattahi MR, Sepehrimanesh M, Safarpour A, Malekhosseini SA, Nejabat M, Khodadad M, Ardebili M. YMDD Motif Mutation Profile Among Patients Receiving Liver Transplant Due to Hepatitis B Virus Infection With Long Term Lamivudine/Immunoglobulin Therapy. Hepat Mon 2015;15:e27120. [PMID: 26300928 DOI: 10.5812/hepatmon.27120v2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
16 Menéndez-Arias L, Sebastián-Martín A, Álvarez M. Viral reverse transcriptases. Virus Res 2017;234:153-76. [PMID: 28043823 DOI: 10.1016/j.virusres.2016.12.019] [Cited by in Crossref: 49] [Cited by in F6Publishing: 38] [Article Influence: 9.8] [Reference Citation Analysis]
17 Dan YY, Wai CT, Lee YM, Sutedja DS, Seet BL, Lim SG. Outcome of lamivudine-resistant hepatitis B virus is generally benign except in cirrhotics. World J Gastroenterol 2005;11:4344-50. [PMID: 16038032 DOI: 10.3748/wjg.v11.i28.4344] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
18 Jones SA, Hu J. Hepatitis B virus reverse transcriptase: diverse functions as classical and emerging targets for antiviral intervention. Emerg Microbes Infect. 2013;2:e56. [PMID: 26038488 DOI: 10.1038/emi.2013.56] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 6.0] [Reference Citation Analysis]
19 Quarleri J, Moretti F, Bouzas MB, Laufer N, Carrillo MG, Giuliano SF, Pérez H, Cahn P, Salomon H. Hepatitis B virus genotype distribution and its lamivudine-resistant mutants in HIV-coinfected patients with chronic and occult hepatitis B. AIDS Res Hum Retroviruses. 2007;23:525-531. [PMID: 17506609 DOI: 10.1089/aid.2006.0172] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
20 Linauts S, Saldanha J, Strong DM. PRISM hepatitis B surface antigen detection of hepatits B virus minipool nucleic acid testing yield samples. Transfusion. 2008;48:1376-1382. [PMID: 18422847 DOI: 10.1111/j.1537-2995.2008.01698.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
21 Mbayed VA, Piñeiro y Leone FG, Pezzano SC, Campos RH. Molecular characterization of hepatitis B virus genotype A from Argentina and Brazil. Arch Virol 2009;154:525-9. [DOI: 10.1007/s00705-009-0328-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
22 Liu B, Yang JX, Yan L, Zhuang H, Li T. Novel HBV recombinants between genotypes B and C in 3'-terminal reverse transcriptase (RT) sequences are associated with enhanced viral DNA load, higher RT point mutation rates and place of birth among Chinese patients. Infect Genet Evol 2018;57:26-35. [PMID: 29111272 DOI: 10.1016/j.meegid.2017.10.023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
23 Ciftci S, Keskin F, Cakiris A, Akyuz F, Pinarbasi B, Abaci N, Dincer E, Badur S, Kaymakoglu S, Ustek D. Analysis of potential antiviral resistance mutation profiles within the HBV reverse transcriptase in untreated chronic hepatitis B patients using an ultra-deep pyrosequencing method. Diagn Microbiol Infect Dis. 2014;79:25-30. [PMID: 24630522 DOI: 10.1016/j.diagmicrobio.2014.01.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
24 Tanwar S, Dusheiko G. Is There Any Value to Hepatitis B Virus Genotype Analysis? Curr Gastroenterol Rep 2012;14:37-46. [DOI: 10.1007/s11894-011-0233-5] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 5.5] [Reference Citation Analysis]
25 Ji F, Zhou L, Ma S, Li F, Ding H, Zeng C. Dynamic changes of HBV quasispecies and deletion patterns in a chronic hepatitis B patient. J Med Virol. 2009;81:1551-1559. [PMID: 19626620 DOI: 10.1002/jmv.21595] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
26 Buti M, Jardi R, Rodriguez-frias F, Valdes A, Schaper M, Esteban R, Guardia J. Changes in different regions of hepatitis B virus gene in hepatitis B 'e' antigen-negative patients with chronic hepatitis B: the effect of long-term lamivudine therapy. Aliment Pharmacol Ther 2005;21:1349-56. [DOI: 10.1111/j.1365-2036.2005.02503.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
27 Cooley L, Sasadeusz J. Clinical and virological aspects of hepatitis B co-infection in individuals infected with human immunodeficiency virus type-1. J Clin Virol 2003;26:185-93. [PMID: 12600650 DOI: 10.1016/s1386-6532(02)00117-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
28 Lok AS, Zoulim F, Locarnini S, Mangia A, Niro G, Decraemer H, Maertens G, Hulstaert F, De Vreese K, Sablon E. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. J Clin Microbiol 2002;40:3729-34. [PMID: 12354872 DOI: 10.1128/JCM.40.10.3729-3734.2002] [Cited by in Crossref: 111] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
29 Gaia S, Marzano A, Smedile A, Barbon V, Abate ML, Olivero A, Lagget M, Paganin S, Fadda M, Niro G. Four years of treatment with lamivudine: clinical and virological evaluations in HBe antigen-negative chronic hepatitis B. Aliment Pharmacol Ther. 2004;20:281-287. [PMID: 15274664 DOI: 10.1111/j.1365-2036.2004.02073.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
30 Norder H, Couroucé AM, Coursaget P, Echevarria JM, Lee SD, Mushahwar IK, Robertson BH, Locarnini S, Magnius LO. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology. 2004;47:289-309. [PMID: 15564741 DOI: 10.1159/000080872] [Cited by in Crossref: 602] [Cited by in F6Publishing: 575] [Article Influence: 37.6] [Reference Citation Analysis]
31 Pollicino T, Cacciola I, Saffioti F, Raimondo G. Hepatitis B virus PreS/S gene variants: pathobiology and clinical implications. J Hepatol. 2014;61:408-417. [PMID: 24801416 DOI: 10.1016/j.jhep.2014.04.041] [Cited by in Crossref: 146] [Cited by in F6Publishing: 140] [Article Influence: 20.9] [Reference Citation Analysis]
32 Xiong J, Yao YC, Zi XY, Li JX, Wang XM, Ye XT, Zhao SM, Yan YB, Yu HY, Hu YP. Expression of hepatitis B virus X protein in transgenic mice. World J Gastroenterol. 2003;9:112-116. [DOI: 10.3748/wjg.v9.i1.112] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
33 Thedja MD, Roni M, Harahap AR, Siregar NC, Ie SI, Muljono DH. Occult hepatitis B in blood donors in Indonesia: altered antigenicity of the hepatitis B virus surface protein. Hepatol Int. 2010;4:608-614. [PMID: 21063484 DOI: 10.1007/s12072-010-9203-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
34 Gong L, Han Y, Chen L, Liu F, Hao P, Sheng J, Li XH, Yu DM, Gong QM, Tian F. Comparison of next-generation sequencing and clone-based sequencing in analysis of hepatitis B virus reverse transcriptase quasispecies heterogeneity. J Clin Microbiol. 2013;51:4087-4094. [PMID: 24088859 DOI: 10.1128/jcm.01723-13] [Cited by in Crossref: 33] [Cited by in F6Publishing: 17] [Article Influence: 4.1] [Reference Citation Analysis]
35 Katsoulidou A, Paraskevis D, Magiorkinis E, Moschidis Z, Haida C, Hatzitheodorou E, Varaklioti A, Karafoulidou A, Hatzitaki M, Kavallierou L. Molecular characterization of occult hepatitis B cases in Greek blood donors. J Med Virol. 2009;81:815-825. [PMID: 19319945 DOI: 10.1002/jmv.21499] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 3.1] [Reference Citation Analysis]
36 Cha CK, Kwon HC, Cheong JY, Cho SW, Hong SP, Kim SO, Yoo WD. Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B. J Med Virol 2009;81:417-24. [PMID: 19152409 DOI: 10.1002/jmv.21402] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
37 Tacke F, Gehrke C, Luedde T, Heim A, Manns MP, Trautwein C. Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutants. J Virol 2004;78:8524-35. [PMID: 15280461 DOI: 10.1128/JVI.78.16.8524-8535.2004] [Cited by in Crossref: 84] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]
38 Fu Y, Zeng Y, Chen T, Chen H, Lin N, Lin J, Liu X, Huang E, Wu S, Wu S, Xu S, Wang L, Ou Q. Characterization and Clinical Significance of Natural Variability in Hepatitis B Virus Reverse Transcriptase in Treatment-Naive Chinese Patients by Sanger Sequencing and Next-Generation Sequencing. J Clin Microbiol 2019;57:e00119-19. [PMID: 31189581 DOI: 10.1128/JCM.00119-19] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
39 D'Ugo E, Kondili LA, Canitano A, Catone S, Giuseppetti R, Gallinella B, Palmieri G, Orobello S, Argentini C, Glück R. Rapid emergence of a viral resistant mutant in WHV chronically infected woodchucks treated with lamivudine and a pre-S/S CHO-derived hepatitis B virus vaccine. Vaccine. 2007;25:4895-4902. [PMID: 17531355 DOI: 10.1016/j.vaccine.2007.04.030] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
40 Locarnini S. Relevance of HBV mutations in severity and progression of chronic hepatitis B. J Gastroenterol Hepatol 2004;19:S108-12. [DOI: 10.1111/j.1440-1746.2004.03655.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
41 Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, Brown N, Woessner M, Boehme R, Condreay L. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis. 2003;36:687-696. [PMID: 12627352 DOI: 10.1086/368083] [Cited by in Crossref: 454] [Cited by in F6Publishing: 410] [Article Influence: 25.2] [Reference Citation Analysis]
42 Szmaragd C, Nichols RA, Balloux F. A novel approach to characterise pathogen candidate genetic polymorphisms involved in clinical outcome. Infect Genet Evol 2006;6:38-45. [PMID: 16376839 DOI: 10.1016/j.meegid.2005.01.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
43 Panjaworayan N, Roessner SK, Firth AE, Brown CM. HBVRegDB: annotation, comparison, detection and visualization of regulatory elements in hepatitis B virus sequences. Virol J 2007;4:136. [PMID: 18086305 DOI: 10.1186/1743-422X-4-136] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
44 Liu BM, Li T, Xu J, Li XG, Dong JP, Yan P, Yang JX, Yan L, Gao ZY, Li WP, Sun XW, Wang YH, Jiao XJ, Hou CS, Zhuang H. Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-naïve Chinese patients. Antiviral Res 2010;85:512-9. [PMID: 20034521 DOI: 10.1016/j.antiviral.2009.12.006] [Cited by in Crossref: 64] [Cited by in F6Publishing: 62] [Article Influence: 5.3] [Reference Citation Analysis]
45 Costantini A, Marinelli K, Biagioni G, Monachetti A, Ferreri ML, Butini L, Montroni M, Manzin A, Bagnarelli P. Molecular analysis of hepatitis B virus (HBV) in an HIV co-infected patient with reactivation of occult HBV infection following discontinuation of lamivudine-including antiretroviral therapy. BMC Infect Dis. 2011;11:310. [PMID: 22054111 DOI: 10.1186/1471-2334-11-310] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
46 Takamatsu Y, Das D, Kohgo S, Hayashi H, Delino NS, Sarafianos SG, Mitsuya H, Maeda K. The High Genetic Barrier of EFdA/MK-8591 Stems from Strong Interactions with the Active Site of Drug-Resistant HIV-1 Reverse Transcriptase. Cell Chem Biol 2018;25:1268-1278.e3. [PMID: 30174310 DOI: 10.1016/j.chembiol.2018.07.014] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
47 Yokosuka O, Arai M. Molecular biology of hepatitis B virus: effect of nucleotide substitutions on the clinical features of chronic hepatitis B. Med Mol Morphol 2006;39:113-20. [PMID: 16998621 DOI: 10.1007/s00795-006-0328-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
48 Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol 2016;22:18-75. [PMID: 27044762 DOI: 10.3350/cmh.2016.22.1.18] [Cited by in Crossref: 115] [Cited by in F6Publishing: 120] [Article Influence: 23.0] [Reference Citation Analysis]
49 Menéndez-Arias L, Álvarez M, Pacheco B. Nucleoside/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance. Curr Opin Virol. 2014;8:1-9. [PMID: 24814823 DOI: 10.1016/j.coviro.2014.04.005] [Cited by in Crossref: 90] [Cited by in F6Publishing: 80] [Article Influence: 12.9] [Reference Citation Analysis]
50 Sede M, Ojeda D, Cassino L, Westergaard G, Vazquez M, Benetti S, Fay F, Tanno H, Quarleri J. Long-term monitoring drug resistance by ultra-deep pyrosequencing in a chronic hepatitis B virus (HBV)-infected patient exposed to several unsuccessful therapy schemes. Antiviral Res. 2012;94:184-187. [PMID: 22453135 DOI: 10.1016/j.antiviral.2012.03.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
51 Wagner A, Denis F, Ranger-rogez S, Loustaud-ratti V, Alain S. Génotypes du virus de l'hépatite B. Immuno-analyse & Biologie Spécialisée 2004;19:330-42. [DOI: 10.1016/j.immbio.2004.10.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
52 Yang H, Westland CE, Delaney WE 4th, Heathcote EJ, Ho V, Fry J, Brosgart C, Gibbs CS, Miller MD, Xiong S. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology. 2002;36:464-473. [PMID: 12143057 DOI: 10.1053/jhep.2002.34740] [Cited by in Crossref: 133] [Cited by in F6Publishing: 107] [Article Influence: 7.0] [Reference Citation Analysis]
53 Kessler HH, Stelzl E, Marth E, Stauber RE. Detection of Mutations in the Hepatitis B Virus Polymerase Gene. Clinical Chemistry 2003;49:989-92. [DOI: 10.1373/49.6.989] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
54 Villet S, Pichoud C, Villeneuve JP, Trépo C, Zoulim F. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology. 2006;131:1253-1261. [PMID: 17030194 DOI: 10.1053/j.gastro.2006.08.013] [Cited by in Crossref: 125] [Cited by in F6Publishing: 113] [Article Influence: 8.3] [Reference Citation Analysis]
55 Akuta N, Suzuki F, Kobayashi M, Tsubota A, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y. The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment. J Hepatol. 2003;38:315-321. [PMID: 12586297 DOI: 10.1016/s0168-8278(02)00410-5] [Cited by in Crossref: 74] [Cited by in F6Publishing: 18] [Article Influence: 4.1] [Reference Citation Analysis]
56 Sharon A, Chu CK. Understanding the molecular basis of HBV drug resistance by molecular modeling. Antiviral Res 2008;80:339-53. [PMID: 18765256 DOI: 10.1016/j.antiviral.2008.07.010] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
57 Li XG, Liu BM, Xu J, Liu XE, Ding H, Li T. Discrepancy of potential antiviral resistance mutation profiles within the HBV reverse transcriptase between nucleos(t)ide analogue-untreated and -treated patients with chronic hepatitis B in a hospital in China. J Med Virol. 2012;84:207-216. [PMID: 22170539 DOI: 10.1002/jmv.23182] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
58 Vietheer PT, Netter HJ, Sozzi T, Bartholomeusz A. Failure of the lamivudine-resistant rtM204I hepatitis B virus mutants to efficiently support hepatitis delta virus secretion. J Virol. 2005;79:6570-6573. [PMID: 15858045 DOI: 10.1128/jvi.79.10.6570-6573.2005] [Cited by in Crossref: 25] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
59 Qiu L, Chen L, Chen K. Antihepatitis B therapy: a review of current medications and novel small molecule inhibitors. Fundam Clin Pharmacol 2014;28:364-81. [DOI: 10.1111/fcp.12053] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
60 Kim JK, Lee HJ, Lee YJ, Chun JY, Lee IK, Lim YS, Suh DJ, Ko SY, Kim MH, Oh HB. Direct detection of lamivudine-resistant hepatitis B virus mutants by a multiplex PCR using dual-priming oligonucleotide primers. J Virol Methods. 2008;149:76-84. [PMID: 18291537 DOI: 10.1016/j.jviromet.2008.01.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
61 Revill PA, Littlejohn M, Ayres A, Yuen L, Colledge D, Bartholomeusz A, Sasaduesz J, Lewin SR, Dore GJ, Matthews GV, Thio CL, Locarnini SA. Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals. AIDS. 2007;21:1701-1710. [PMID: 17690567 DOI: 10.1097/qad.0b013e32826fb305] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
62 Fan W, Huang L, Zhou Z, Li Y. A336C/A336T/T337C variations in HBV core gene and spontaneous hepatitis B e antigen loss in chronic hepatitis B patients. Virol J 2011;8:226. [PMID: 21569538 DOI: 10.1186/1743-422X-8-226] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
63 Aloman C, Wands JR. Resistance of HBV to adefovir dipivoxil: a case for combination antiviral therapy. Hepatology. 2003;38:1584-1587. [PMID: 14655682 DOI: 10.1002/hep.510380633] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
64 Zhong JH, Li le Q, Wu LC. Lamivudine with or without adefovir dipivoxil for postoperative hepatocellular carcinoma. Cochrane Database Syst Rev. 2011;CD008713. [PMID: 22161435 DOI: 10.1002/14651858.cd008713.pub2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
65 Villet S, Pichoud C, Billioud G, Barraud L, Durantel S, Trépo C, Zoulim F. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol. 2008;48:747-755. [PMID: 18331765 DOI: 10.1016/j.jhep.2008.01.027] [Cited by in Crossref: 143] [Cited by in F6Publishing: 136] [Article Influence: 11.0] [Reference Citation Analysis]
66 Kuiken C, Combet C, Bukh J, Shin-I T, Deleage G, Mizokami M, Richardson R, Sablon E, Yusim K, Pawlotsky JM, Simmonds P; Los Alamos HIV Database Group. A comprehensive system for consistent numbering of HCV sequences, proteins and epitopes. Hepatology 2006;44:1355-61. [PMID: 17058236 DOI: 10.1002/hep.21377] [Cited by in Crossref: 86] [Cited by in F6Publishing: 84] [Article Influence: 5.7] [Reference Citation Analysis]
67 Torresi J. The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. J Clin Virol. 2002;25:97-106. [PMID: 12367644 DOI: 10.1016/s1386-6532(02)00049-5] [Cited by in Crossref: 123] [Cited by in F6Publishing: 63] [Article Influence: 6.5] [Reference Citation Analysis]
68 Yang Y, Zhang Q, Cai C, Lu M, Li X, Jiang N, Jiang H, Xu C, Li H, Wang G, Yi S, Zhang J, Zhang J, Yi H, Zhang Y, Chen G. Prophylaxis of hepatitis B recurrence in post-liver transplantation patients with lamivudine-resistant YMDD mutant: . Chinese Medical Journal 2007;120:1400-3. [DOI: 10.1097/00029330-200708020-00004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
69 Di Marco V, Marzano A, Lampertico P, Andreone P, Santantonio T, Almasio PL, Rizzetto M, Craxì A. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology. 2004;40:883-891. [PMID: 15382125 DOI: 10.1002/hep.1840400418] [Cited by in Crossref: 153] [Cited by in F6Publishing: 101] [Article Influence: 9.0] [Reference Citation Analysis]
70 Carosi G, Rizzetto M. Treatment of chronic hepatitis B: recommendations from an Italian workshop. Dig Liver Dis. 2008;40:603-617. [PMID: 18499540 DOI: 10.1016/j.dld.2008.03.011] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 3.2] [Reference Citation Analysis]
71 Thibault V, Aubron-olivier C, Agut H, Katlama C. Primary infection with a lamivudine-resistant hepatitis B virus: . AIDS 2002;16:131-3. [DOI: 10.1097/00002030-200201040-00020] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 3.1] [Reference Citation Analysis]
72 Nakanishi H, Kurosaki M, Asahina Y, Onuki Y, Ueda K, Nishimura Y, Tsuchiya K, Kitamura T, Uchihara M, Miyake S, Enomoto N, Izumi N. Polymerase Domain B Mutation Is Associated with Hepatitis Relapse during Long-Term Lamivudine Therapy for Chronic Hepatitis B. Intervirology 2005;48:381-8. [DOI: 10.1159/000086065] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
73 Leemans WF, Janssen HL, Niesters HG, de Man RA. Switching patients with lamivudine resistant chronic hepatitis B virus from tenofovir to adefovir results in less potent HBV-DNA suppression. J Viral Hepat. 2008;15:108-114. [PMID: 18184193 DOI: 10.1111/j.1365-2893.2007.00906.x] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
74 Lieshout-krikke RW, Molenaar-de Backer MWA, Swieten P, Zaaijer HL. Surface antigen-negative hepatitis B virus infection in Dutch blood donors. Eur J Clin Microbiol Infect Dis 2014;33:69-77. [DOI: 10.1007/s10096-013-1930-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
75 Zou W, Qian F, Jin F, Li D, Chen J. Characterization of mutations in the reverse transcriptase region of hepatitis B virus in treated and untreated chronic hepatitis B patients. Trans R Soc Trop Med Hyg 2021;115:870-7. [PMID: 33236067 DOI: 10.1093/trstmh/traa142] [Reference Citation Analysis]
76 León P, Pozo F, Echevarría JM. Detection of hepatitis B virus variants resistant to lamivudine and famciclovir among randomly selected chronic carriers from Spain. Enferm Infecc Microbiol Clin 2004;22:133-7. [PMID: 14987532 DOI: 10.1016/s0213-005x(04)73051-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
77 Korean Association for the Study of the Liver. KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol. 2012;18:109-162. [PMID: 22893865 DOI: 10.3350/cmh.2012.18.2.109] [Cited by in Crossref: 109] [Cited by in F6Publishing: 118] [Article Influence: 12.1] [Reference Citation Analysis]
78 Yim HJ, Hussain M, Liu Y, Wong SN, Fung SK, Lok AS. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology. 2006;44:703-712. [PMID: 16941700 DOI: 10.1002/hep.21290] [Cited by in Crossref: 190] [Cited by in F6Publishing: 170] [Article Influence: 12.7] [Reference Citation Analysis]
79 Seignères B, Martin P, Werle B, Schorr O, Jamard C, Rimsky L, Trépo C, Zoulim F. Effects of pyrimidine and purine analog combinations in the duck hepatitis B virus infection model. Antimicrob Agents Chemother. 2003;47:1842-1852. [PMID: 12760857 DOI: 10.1128/aac.47.6.1842-1852.2003] [Cited by in Crossref: 37] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
80 Singh H, Pradhan M, Singh RL, Phadke S, Naik SR, Aggarwal R, Naik S. High frequency of hepatitis B virus infection in patients with beta-thalassemia receiving multiple transfusions. Vox Sang 2003;84:292-9. [DOI: 10.1046/j.1423-0410.2003.00300.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 1.6] [Reference Citation Analysis]
81 Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, Plym M, Pokornowski K, Yu CF, Angus P. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother. 2004;48:3498-3507. [PMID: 15328117 DOI: 10.1128/aac.48.9.3498-3507.2004] [Cited by in Crossref: 407] [Cited by in F6Publishing: 115] [Article Influence: 23.9] [Reference Citation Analysis]
82 Levitsky J, Doucette K; the AST Infectious Diseases Community of Practice. Viral Hepatitis in Solid Organ Transplant Recipients. American Journal of Transplantation 2009;9:S116-30. [DOI: 10.1111/j.1600-6143.2009.02902.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
83 Delaney WE 4th, Locarnini S, Shaw T. Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation. Antivir Chem Chemother. 2001;12:1-35. [PMID: 11437320 DOI: 10.1177/095632020101200101] [Cited by in Crossref: 73] [Cited by in F6Publishing: 64] [Article Influence: 3.8] [Reference Citation Analysis]
84 Ntziora F, Paraskevis D, Haida C, Magiorkinis E, Manesis E, Papatheodoridis G, Manolakopoulos S, Beloukas A, Chryssoy S, Magiorkinis G. Quantitative detection of the M204V hepatitis B virus minor variants by amplification refractory mutation system real-time PCR combined with molecular beacon technology. J Clin Microbiol. 2009;47:2544-2550. [PMID: 19553583 DOI: 10.1128/JCM.00045-09] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
85 Wen J. Clinical Application of Pyrosequencing in Detection of YMDD Mutations. Laboratory Medicine 2007;38:1-7. [DOI: 10.1309/ppfyy6wjwa3fe7gg] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
86 Cheng H, Zhang HZ, Shen WA, Liu YF, Ma FC. Expression of RNase H of human hepatitis B virus polymerase in Escherichia coli. World J Gastroenterol 2003;9:513-5. [PMID: 12632508 DOI: 10.3748/wjg.v9.i3.513] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
87 Iyer RP, Jin Y, Roland A, Morrey JD, Mounir S, Korba B. Phosphorothioate di- and trinucleotides as a novel class of anti-hepatitis B virus agents. Antimicrob Agents Chemother. 2004;48:2199-2205. [DOI: 10.1128/AAC.48.6.2199-2205.2004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
88 Walters KA, Tipples GA, Allen MI, Condreay LD, Addison WR, Tyrrell L. Generation of stable cell lines expressing Lamivudine-resistant hepatitis B virus for antiviral-compound screening. Antimicrob Agents Chemother 2003;47:1936-42. [PMID: 12760870 DOI: 10.1128/AAC.47.6.1936-1942.2003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
89 Kim KH, Kim ND, Seong BL. Discovery and development of anti-HBV agents and their resistance. Molecules. 2010;15:5878-5908. [PMID: 20802402 DOI: 10.3390/molecules15095878] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 3.6] [Reference Citation Analysis]
90 Lau GK, He ML, Fong DY, Bartholomeusz A, Au WY, Lie AK, Locarnini S, Liang R. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology. 2002;36:702-709. [PMID: 12198664 DOI: 10.1053/jhep.2002.35068] [Cited by in Crossref: 132] [Cited by in F6Publishing: 114] [Article Influence: 6.9] [Reference Citation Analysis]
91 Lee JY, Locarnini S. Hepatitis B virus: pathogenesis, viral intermediates, and viral replication. Clin Liver Dis. 2004;8:301-320. [PMID: 15481342 DOI: 10.1016/j.cld.2004.02.009] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
92 Erdem A, Sayar F, Karadeniz H, Guven G, Ozsoz M, Piskin E. Development of Streptavidin Carrying Magnetic Nanoparticles and Their Applications in Electrochemical Nucleic Acid Sensor Systems. Electroanalysis 2007;19:798-804. [DOI: 10.1002/elan.200603774] [Cited by in Crossref: 47] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
93 Thabut D, Thibault V, Bernard-Chabert B, Mouquet C, Di Martino V, Le Calvez S, Opolon P, Benhamou Y, Bitker MO, Poynard T. Long-term therapy with lamivudine in renal transplant recipients with chronic hepatitis B. Eur J Gastroenterol Hepatol 2004;16:1367-73. [PMID: 15618847 DOI: 10.1097/00042737-200412000-00022] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
94 Thio CL. Hepatitis B virus infection in HIV-infected persons. Curr hepatitis rep 2004;3:91-7. [DOI: 10.1007/s11901-004-0015-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
95 Tseng T, Liu C, Wang C, Chen P, Lai M, Kao J, Chen D. A higher alanine aminotransferase level correlates with earlier hepatitis B e antigen seroconversion in lamivudine-treated chronic hepatitis B patients: ALT level and HBeAg seroconversion. Liver International 2008;28:1034-41. [DOI: 10.1111/j.1478-3231.2008.01766.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
96 Devesa M, Rodríguez C, León G, Liprandi F, Pujol FH. Clade analysis and surface antigen polymorphism of hepatitis B virus American genotypes. J Med Virol. 2004;72:377-384. [PMID: 14748061 DOI: 10.1002/jmv.20015] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 2.5] [Reference Citation Analysis]
97 Cooper SL, King WC, Mogul DB, Ghany MG, Schwarz KB; Hepatitis B Research Network (HBRN). Clinical significance of quantitative e antigen in a cohort of hepatitis B virus-infected children and adults in North America. J Viral Hepat 2021;28:1042-56. [PMID: 33893706 DOI: 10.1111/jvh.13520] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Teng X, Xu W, Hao M, Fang Y, Zhao Y, Chen S, Li D, Gu H. Differential inhibition of lamivudine-resistant hepatitis B virus by allele-specific RNAi. Journal of Virological Methods 2010;168:6-12. [DOI: 10.1016/j.jviromet.2010.04.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
99 Enomoto M, Tamori A, Kohmoto MT, Morikawa H, Habu D, Sakaguchi H, Takeda T, Seki S, Kawada N, Shiomi S, Nishiguchi S. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: Analyses of the polymerase gene and full-length sequences. J Med Virol 2007;79:1664-70. [DOI: 10.1002/jmv.20984] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
100 Tse KC, Yap DY, Tang CS, Yung S, Chan TM. Response to adefovir or entecavir in renal allograft recipients with hepatitic flare due to lamivudine-resistant hepatitis B. Clin Transplant. 2010;24:207-212. [PMID: 19758269 DOI: 10.1111/j.1399-0012.2009.01090.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
101 Delaney WE 4th, Edwards R, Colledge D, Shaw T, Furman P, Painter G, Locarnini S. Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro. Antimicrob Agents Chemother. 2002;46:3057-3060. [PMID: 12183271 DOI: 10.1128/aac.46.9.3057-3060.2002] [Cited by in Crossref: 117] [Cited by in F6Publishing: 54] [Article Influence: 6.5] [Reference Citation Analysis]
102 Pondé RA, Cardoso DD, Ferro MO. The underlying mechanisms for the 'anti-HBc alone' serological profile. Arch Virol 2010;155:149-58. [PMID: 20091193 DOI: 10.1007/s00705-009-0559-6] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 3.3] [Reference Citation Analysis]
103 Buti M. Actualización en el tratamiento de la hepatitis crónica B. Gastroenterología y Hepatología 2004;27:55-7. [DOI: 10.1016/s0210-5705(03)79087-6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
104 Eisenbach C, Sauer P, Mehrabi A, Stremmel W, Encke J. Prevention of hepatitis B virus recurrence after liver transplantation. Clin Transplant 2006;20 Suppl 17:111-6. [PMID: 17100710 DOI: 10.1111/j.1399-0012.2006.00609.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
105 Zöllner B, Petersen J, Puchhammer-Stöckl E, Kletzmayr J, Sterneck M, Fischer L, Schröter M, Laufs R, Feucht HH. Viral features of lamivudine resistant hepatitis B genotypes A and D. Hepatology. 2004;39:42-50. [PMID: 14752821 DOI: 10.1002/hep.20016] [Cited by in Crossref: 79] [Cited by in F6Publishing: 78] [Article Influence: 4.6] [Reference Citation Analysis]
106 Shaw T, Bartholomeusz A, Locarnini S. HBV drug resistance: mechanisms, detection and interpretation. J Hepatol. 2006;44:593-606. [PMID: 16455151 DOI: 10.1016/j.jhep.2006.01.001] [Cited by in Crossref: 148] [Cited by in F6Publishing: 139] [Article Influence: 9.9] [Reference Citation Analysis]
107 Villet S, Ollivet A, Pichoud C, Barraud L, Villeneuve JP, Trépo C, Zoulim F. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol. 2007;46:531-538. [PMID: 17239478 DOI: 10.1016/j.jhep.2006.11.016] [Cited by in Crossref: 117] [Cited by in F6Publishing: 110] [Article Influence: 7.8] [Reference Citation Analysis]
108 Kumar M, Sarin SK. Pharmacology, clinical efficacy and safety of lamivudine in hepatitis B virus infection. Expert Review of Gastroenterology & Hepatology 2014;2:465-95. [DOI: 10.1586/17474124.2.4.465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
109 Li J, Du Y, Liu X, Shen QC, Huang AL, Zheng MY, Luo XM, Jiang HL. Binding sensitivity of adefovir to the polymerase from different genotypes of HBV: molecular modeling, docking and dynamics simulation studies. Acta Pharmacol Sin 2013;34:319-28. [PMID: 23202802 DOI: 10.1038/aps.2012.146] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
110 Cheng X, Guan W, Sun S, Li B, Li H, Kang F, Kang J, Yang D, Nassal M, Sun D. Stable Human Hepatoma Cell Lines for Efficient Regulated Expression of Nucleoside/Nucleotide Analog Resistant and Vaccine Escape Hepatitis B Virus Variants and Woolly Monkey Hepatitis B Virus. PLoS One 2015;10:e0145746. [PMID: 26699621 DOI: 10.1371/journal.pone.0145746] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
111 Ahn SH, Yuen L, Han KH, Littlejohn M, Chang HY, Damerow H, Ayres A, Heo J, Locarnini S, Revill PA. Molecular and clinical characteristics of hepatitis B virus in Korea. J Med Virol. 2010;82:1126-1134. [PMID: 20513074 DOI: 10.1002/jmv.21844] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
112 Jones LR, Sede M, Manrique JM, Quarleri J. Hepatitis B virus resistance substitutions: long-term analysis by next-generation sequencing. Arch Virol 2016;161:2885-91. [PMID: 27447462 DOI: 10.1007/s00705-016-2959-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
113 Rosen H. Hepatitis B and C in the liver transplant recipient: Current understanding and treatment. Liver Transplantation 2001;7:S87-98. [DOI: 10.1053/jlts.2001.28519] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
114 Bracho MA, Gosalbes MJ, González F, Moya A, González-Candelas F. Molecular epidemiology and evolution in an outbreak of fulminant hepatitis B virus. J Clin Microbiol 2006;44:1288-94. [PMID: 16597853 DOI: 10.1128/JCM.44.4.1288-1294.2006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
115 Nguyen MH, Wright TL. Therapeutic advances in the management of hepatitis B and hepatitis C. Curr Opin Infect Dis. 2001;14:593-601. [PMID: 11964881 DOI: 10.1097/00001432-200110000-00014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
116 Woo HY, Park H, Kim BI, Jeon WK, Kim YJ. Evaluation of dual priming oligonucleotide-based multiplex PCR for detection of HBV YMDD mutants. Arch Virol. 2008;153:2019-2025. [PMID: 18836856 DOI: 10.1007/s00705-008-0218-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
117 Sueki R, Maekawa S, Miura M, Kadokura M, Komase K, Shindo H, Kanayama A, Ohmori T, Shindo K, Amemiya F, Nakayama Y, Uetake T, Inoue T, Sakamoto M, Enomoto N. Correlation between pretreatment viral sequences and the emergence of lamivudine resistance in hepatitis B virus infection. J Med Virol 2012;84:1360-8. [PMID: 22825814 DOI: 10.1002/jmv.23314] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
118 Tsubota A. How do naturally occurring YMDD-motif mutants influence the clinical course of lamivudine-naïve patients with chronic hepatitis B virus infection? J Gastroenterol Hepatol 2006;21:1769-71. [PMID: 17074012 DOI: 10.1111/j.1440-1746.2006.04768.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
119 Conjeevaram HS, Lok AS. Management of chronic hepatitis B. Journal of Hepatology 2003;38:90-103. [DOI: 10.1016/s0168-8278(02)00431-2] [Cited by in Crossref: 122] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
120 Wang F, Lu L, Yu C, Lv Z, Luo X, Wan C, Hu Z, Zhu Q, Deng Y, Zhang C. Development of a novel DNA sequencing method not only for hepatitis B virus genotyping but also for drug resistant mutation detection. BMC Med Genomics 2013;6 Suppl 1:S15. [PMID: 23369292 DOI: 10.1186/1755-8794-6-S1-S15] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
121 Nassal M. Hepatitis B viruses: reverse transcription a different way. Virus Res. 2008;134:235-249. [PMID: 18339439 DOI: 10.1016/j.virusres.2007.12.024] [Cited by in Crossref: 260] [Cited by in F6Publishing: 233] [Article Influence: 20.0] [Reference Citation Analysis]
122 Xu J, Wu B, Wang JH, Huang L, Wang DY, Zhao L, Zhao GP, Wang Y. Pre-existing mutations in reverse transcriptase of hepatitis B virus in treatment-naive Chinese patients with chronic hepatitis B. PLoS One. 2015;10:e0117429. [PMID: 25821965 DOI: 10.1371/journal.pone.0117429] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
123 Bang KB, Kim HJ. Management of antiviral drug resistance in chronic hepatitis B. World J Gastroenterol. 2014;20:11641-11649. [PMID: 25206270 DOI: 10.3748/wjg.v20.i33.11641] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
124 Hui CK, Yu J, Au WY, Zhang HY, Bartholomeusz A, Locarnini S, Kwong YL, Liang R, Lau GK. Sexual transmission of hepatitis B infection despite the presence of hepatitis B virus immunity in recipients of allogeneic bone marrow transplantation. J Clin Virol 2005;32:173-8. [PMID: 15653422 DOI: 10.1016/j.jcv.2004.08.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
125 Warner N, Locarnini S, Kuiper M, Bartholomeusz A, Ayres A, Yuen L, Shaw T. The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. Antimicrob Agents Chemother. 2007;51:2285-2292. [PMID: 17438047 DOI: 10.1128/aac.01499-06] [Cited by in Crossref: 68] [Cited by in F6Publishing: 30] [Article Influence: 4.9] [Reference Citation Analysis]
126 Margeridon-Thermet S, Shafer RW. Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C. Viruses. 2010;2:2696-2739. [PMID: 21243082 DOI: 10.3390/v2122696] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
127 Zhang K, Imazeki F, Fukai K, Arai M, Kanda T, Mikata R, Yokosuka O. Analysis of the complete hepatitis B virus genome in patients with genotype C chronic hepatitis in relation to HBeAg and anti-HBe. J Med Virol 2007;79:683-93. [DOI: 10.1002/jmv.20849] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
128 Thio CL. Chronic hepatitis B or C in HIV-infected persons: pathogenesis and management. J Gastroenterol Hepatol 2004;19:S138-44. [DOI: 10.1111/j.1440-1746.2004.03665.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
129 Pollicino T, Raffa G, Costantino L, Lisa A, Campello C, Squadrito G, Levrero M, Raimondo G. Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma. Hepatology. 2007;45:277-285. [PMID: 17256766 DOI: 10.1002/hep.21529] [Cited by in Crossref: 109] [Cited by in F6Publishing: 107] [Article Influence: 7.8] [Reference Citation Analysis]
130 Lam YF, Yuen MF, Seto WK, Lai CL. Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety. Curr Hepat Rep. 2011;10:235-243. [PMID: 22131901 DOI: 10.1007/s11901-011-0109-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
131 Olivero A, Ciancio A, Abate ML, Gaia S, Smedile A, Rizzetto M. Performance of sequence analysis, INNO-LiPA line probe assays and AFFIGENE assays in the detection of hepatitis B virus polymerase and precore/core promoter mutations. J Viral Hepat 2006;13:355-62. [DOI: 10.1111/j.1365-2893.2005.00693.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
132 van Bömmel F, Zöllner B, Sarrazin C, Spengler U, Hüppe D, Möller B, Feucht HH, Wiedenmann B, Berg T. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology. 2006;44:318-325. [PMID: 16871563 DOI: 10.1002/hep.21253] [Cited by in Crossref: 208] [Cited by in F6Publishing: 177] [Article Influence: 13.9] [Reference Citation Analysis]
133 Zehender G, De Maddalena C, Giambelli C, Milazzo L, Schiavini M, Bruno R, Tanzi E, Galli M. Different evolutionary rates and epidemic growth of hepatitis B virus genotypes A and D. Virology. 2008;380:84-90. [PMID: 18715605 DOI: 10.1016/j.virol.2008.07.009] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 2.2] [Reference Citation Analysis]
134 Hoa PT, Huy NT, Thu le T, Nga CN, Nakao K, Eguchi K, Chi NH, Hoang BH, Hirayama K. Randomized controlled study investigating viral suppression and serological response following pre-S1/pre-S2/S vaccine therapy combined with lamivudine treatment in HBeAg-positive patients with chronic hepatitis B. Antimicrob Agents Chemother. 2009;53:5134-5140. [PMID: 19770281 DOI: 10.1128/aac.00276-09] [Cited by in Crossref: 38] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
135 Ismail AM, Sharma OP, Kumar MS, Kannangai R, Abraham P. Impact of rtI233V mutation in hepatitis B virus polymerase protein and adefovir efficacy: Homology modeling and molecular docking studies. Bioinformation. 2013;9:121-125. [PMID: 23423477 DOI: 10.6026/97320630009121] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
136 Hartman C, Berkowitz D, Eshach-Adiv O, Hino B, Rimon N, Satinger I, Kra-Oz T, Shamir R. Long-term lamivudine therapy for chronic hepatitis B infection in children unresponsive to interferon. J Pediatr Gastroenterol Nutr. 2006;43:494-498. [PMID: 17033525 DOI: 10.1097/01.mpg.0000235982.34323.67] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
137 Wagner AA, Denis F, Weinbreck P, Loustaud V, Autofage F, Rogez S, Alain S. Serological pattern 'anti-hepatitis B core alone' in HIV or hepatitis C virus-infected patients is not fully explained by hepatitis B surface antigen mutants. AIDS 2004;18:569-71. [PMID: 15090814 DOI: 10.1097/00002030-200402200-00028] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 2.2] [Reference Citation Analysis]
138 Li Y, Zhu M, Guo Y, Chen W, Li G. Full-length hepatitis B virus sequences from naïve patients with fluctuation of viral load during ADV monotherapy. Virus Genes. 2010;40:155-162. [PMID: 20012680 DOI: 10.1007/s11262-009-0429-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
139 Kuiken C, Simmonds P. Nomenclature and numbering of the hepatitis C virus. Methods Mol Biol. 2009;510:33-53. [PMID: 19009252 DOI: 10.1007/978-1-59745-394-3_4] [Cited by in Crossref: 98] [Cited by in F6Publishing: 95] [Article Influence: 8.2] [Reference Citation Analysis]
140 Kay A, Zoulim F. Hepatitis B virus genetic variability and evolution. Virus Res. 2007;127:164-176. [PMID: 17383765 DOI: 10.1016/j.virusres.2007.02.021] [Cited by in Crossref: 173] [Cited by in F6Publishing: 170] [Article Influence: 12.4] [Reference Citation Analysis]
141 Niesters HG, Pas S, de Man RA. Detection of hepatitis B virus genotypes and mutants: current status. J Clin Virol 2005;34 Suppl 1:S4-8. [PMID: 16461222 DOI: 10.1016/s1386-6532(05)80002-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
142 Qian F, Zou W, Jin F, Li D, Shen Y. Prevalence of Potential Resistance Related Variants Among Chinese Chronic Hepatitis B Patients Not Receiving Nucleos(T)ide Analogues. Infect Drug Resist 2020;13:2407-16. [PMID: 32765014 DOI: 10.2147/IDR.S249476] [Reference Citation Analysis]
143 Akuta N, Tsubota A, Suzuki F, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K. Long-term prognosis by lamivudine monotherapy for severe acute exacerbation in chronic hepatitis B infection: emergence of YMDD motif mutant and risk of breakthrough hepatitis - an open-cohort study. J Hepatol. 2003;38:91-97. [PMID: 12480565 DOI: 10.1016/S0168-8278(02)00335-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
144 Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology. 2009;137:1593-1608.e1-e2. [PMID: 19737565 DOI: 10.1053/j.gastro.2009.08.063] [Cited by in Crossref: 468] [Cited by in F6Publishing: 431] [Article Influence: 39.0] [Reference Citation Analysis]
145 Tan Y, Ding K, Su J, Trinh X, Peng Z, Gong Y, Chen L, Cui Q, Lei N, Chen X, Yu R. The naturally occurring YMDD mutation among patients chronically infected HBV and untreated with lamivudine: A systematic review and meta-analysis. PLoS One. 2012;7:e32789. [PMID: 22479339 DOI: 10.1371/journal.pone.0032789] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
146 Mallory MA, Page SR, Hillyard DR. Development and validation of a hepatitis B virus DNA sequencing assay for assessment of antiviral resistance, viral genotype and surface antigen mutation status. J Virol Methods 2011;177:31-7. [PMID: 21723325 DOI: 10.1016/j.jviromet.2011.06.009] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
147 Sablon E, Shapiro F. Advances in Molecular Diagnosis of HBV Infection and Drug Resistance. Int J Med Sci. 2005;2:8-16. [PMID: 15968334 DOI: 10.7150/ijms.2.8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
148 Locarnini S, Omata M. Molecular virology of hepatitis B virus and the development of antiviral drug resistance. Liver International 2006;26:11-22. [DOI: 10.1111/j.1478-3231.2006.01371.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
149 Chen RY, Edwards R, Shaw T, Colledge D, Delaney WE, Isom H, Bowden S, Desmond P, Locarnini SA. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology. 2003;37:27-35. [PMID: 12500185 DOI: 10.1053/jhep.2003.50012] [Cited by in Crossref: 92] [Cited by in F6Publishing: 87] [Article Influence: 5.1] [Reference Citation Analysis]
150 Gaillard RK, Barnard J, Lopez V, Hodges P, Bourne E, Johnson L, Allen MI, Condreay P, Miller WH, Condreay LD. Kinetic analysis of wild-type and YMDD mutant hepatitis B virus polymerases and effects of deoxyribonucleotide concentrations on polymerase activity. Antimicrob Agents Chemother. 2002;46:1005-1013. [PMID: 11897582 DOI: 10.1128/aac.46.4.1005-1013.2002] [Cited by in Crossref: 35] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
151 Locarnini S. Hepatitis B viral resistance: mechanisms and diagnosis. Journal of Hepatology 2003;39:124-32. [DOI: 10.1016/s0168-8278(03)00318-0] [Cited by in Crossref: 58] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
152 Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45:507-539. [PMID: 17256718 DOI: 10.1002/hep.21513] [Cited by in Crossref: 1675] [Cited by in F6Publishing: 1482] [Article Influence: 119.6] [Reference Citation Analysis]
153 Yamamoto T, Litwin S, Zhou T, Zhu Y, Condreay L, Furman P, Mason WS. Mutations of the woodchuck hepatitis virus polymerase gene that confer resistance to lamivudine and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil. J Virol. 2002;76:1213-1223. [PMID: 11773397 DOI: 10.1128/jvi.76.3.1213-1223.2002] [Cited by in Crossref: 26] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
154 Younger HM, Bathgate AJ, Hayes PC. Review article: Nucleoside analogues for the treatment of chronic hepatitis B. Aliment Pharmacol Ther 2004;20:1211-30. [PMID: 15606384 DOI: 10.1111/j.1365-2036.2004.02211.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
155 Manolakopoulos S, Karatapanis S, Elefsiniotis J, Mathou N, Vlachogiannakos J, Iliadou E, Kougioumtzan A, Economou M, Triantos C, Tzourmakliotis D. Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection. Am J Gastroenterol. 2004;99:57-63. [PMID: 14687142 DOI: 10.1046/j.1572-0241.2003.04021.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 3.3] [Reference Citation Analysis]
156 Sablon E, Shapiro F, Zoulim F. Early detection of hepatitis B drug resistance: implications for patient management. Expert Rev Mol Diagn 2003;3:535-47. [PMID: 14510175 DOI: 10.1586/14737159.3.5.535] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
157 Zheng J, Zeng Z, Zhang D, Yu Y, Wang F, Pan CQ. Prevalence and significance of Hepatitis B reverse transcriptase mutants in different disease stages of untreated patients. Liver Int. 2012;32:1535-1542. [PMID: 22882650 DOI: 10.1111/j.1478-3231.2012.02859.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
158 Fournier C, Zoulim F. Antiviral therapy of chronic hepatitis B: prevention of drug resistance. Clin Liver Dis. 2007;11:869-892, ix. [PMID: 17981233 DOI: 10.1016/j.cld.2007.08.013] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
159 Shen H, Alsatie M, Eckert G, Chalasani N, Lumeng L, Kwo PY. Combination therapy with lamivudine and famciclovir for chronic hepatitis B infection. Clin Gastroenterol Hepatol. 2004;2:330-336. [PMID: 15067628 DOI: 10.1016/S1542-3565(04)00063-1] [Cited by in Crossref: 6] [Article Influence: 0.4] [Reference Citation Analysis]
160 Shaw T, Locarnini S. Entecavir for the treatment of chronic hepatitis B. Expert Rev Anti Infect Ther. 2004;2:853-871. [PMID: 15566330 DOI: 10.1586/14789072.2.6.853] [Cited by in Crossref: 35] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
161 Marrone A, Zampino R, Karayannis P, Cirillo G, Cesaro G, Guerrera B, Ricciotti R, del Giudice EM, Utili R, Adinolfi LE, Ruggiero G. Clinical reactivation during lamivudine treatment correlates with mutations in the precore/core promoter and polymerase regions of hepatitis B virus in patients with anti-hepatitis B e-positive chronic hepatitis. Aliment Pharmacol Ther 2005;22:707-14. [PMID: 16197491 DOI: 10.1111/j.1365-2036.2005.02653.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
162 Chan TM, Tse KC, Tang CSO, Lai KN, Ho SKN. Prospective Study on Lamivudine-Resistant Hepatitis B in Renal Allograft Recipients. Am J Transplant 2004;4:1103-9. [DOI: 10.1111/j.1600-6143.2004.00467.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
163 De Maddalena C, Giambelli C, Tanzi E, Colzani D, Schiavini M, Milazzo L, Bernini F, Ebranati E, Cargnel A, Bruno R. High level of genetic heterogeneity in S and P genes of genotype D hepatitis B virus. Virology. 2007;365:113-124. [PMID: 17451771 DOI: 10.1016/j.virol.2007.03.015] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 3.6] [Reference Citation Analysis]
164 Chan TM, Fang GX, Tang CS, Cheng IK, Lai KN, Ho SK. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology. 2002;36:1246-1252. [PMID: 12395336 DOI: 10.1053/jhep.2002.36156] [Cited by in Crossref: 130] [Cited by in F6Publishing: 108] [Article Influence: 6.8] [Reference Citation Analysis]
165 Lee HW, Lee HJ, Hwang JS, Sohn JH, Jang JY, Han KJ, Park JY, Kim DY, Ahn SH, Paik YH, Lee CK, Lee KS, Chon CY, Han KH. Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. Hepatology. 2010;51:415-421. [PMID: 19902424 DOI: 10.1002/hep.23323] [Cited by in Crossref: 91] [Cited by in F6Publishing: 77] [Article Influence: 8.3] [Reference Citation Analysis]
166 Vassiliadis T, Nikolaidis N, Giouleme O, Tziomalos K, Grammatikos N, Patsiaoura K, Zezos P, Gkisakis D, Theodoropoulos K, Katsinelos P, Orfanou-Koumerkeridou E, Eugenidis N. Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B. Aliment Pharmacol Ther 2005;21:531-7. [PMID: 15740536 DOI: 10.1111/j.1365-2036.2005.02388.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
167 Santana LC, Mantovani NP, Ferreira MC, Arnold R, Duro RL, Ferreira PR, Hunter JR, Leal É, Diaz RS, Komninakis SV. Identification of a new hepatitis B virus recombinant D2/D3 in the city of São Paulo, Brazil. Arch Virol 2017;162:457-67. [PMID: 27787680 DOI: 10.1007/s00705-016-3122-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
168 Choi YM, Lee SY, Kim BJ. Naturally occurring hepatitis B virus reverse transcriptase mutations related to potential antiviral drug resistance and liver disease progression. World J Gastroenterol. 2018;24:1708-1724. [PMID: 29713126 DOI: 10.3748/wjg.v24.i16.1708] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
169 Filippini P, Coppola N, Pisapia R, Scolastico C, Marrocco C, Zaccariello A, Nacca C, Sagnelli C, De Stefano G, Ferraro T, De Stefano C, Sagnelli E. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. AIDS. 2006;20:1253-1260. [PMID: 16816553 DOI: 10.1097/01.aids.0000232232.41877.2a] [Cited by in Crossref: 83] [Cited by in F6Publishing: 80] [Article Influence: 5.5] [Reference Citation Analysis]
170 Leemans WF, Niesters HG, van der Eijk AA, Janssen HL, Schalm SW, de Man RA. Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir. Eur J Gastroenterol Hepatol 2008;20:773-7. [PMID: 18617782 DOI: 10.1097/MEG.0b013e3282f793d6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
171 Ramos B, Núñez M, Martín-carbonero L, Sheldon J, Rios P, Labarga P, Romero M, Barreiro P, García-samaniego J, Soriano V. Hepatitis B Virus Genotypes and Lamivudine Resistance Mutations in HIV/Hepatitis B Virus-Coinfected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes 2007;44:557-61. [DOI: 10.1097/qai.0b013e3180314b46] [Cited by in Crossref: 36] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
172 Hafkemeyer P, Brinkmann U, Brinkmann E, Pastan I, Blum HE, Baumert TF. Pseudomonas exotoxin antisense RNA selectively kills hepatitis B virus infected cells. World J Gastroenterol. 2008;14:2810-2817. [PMID: 18473403 DOI: 10.3748/wjg.14.2810] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
173 Araujo NM, Branco-Vieira M, Silva AC, Pilotto JH, Grinsztejn B, de Almeida AJ, Trepo C, Gomes SA. Occult hepatitis B virus infection in HIV-infected patients: Evaluation of biochemical, virological and molecular parameters. Hepatol Res. 2008;38:1194-1203. [PMID: 18624719 DOI: 10.1111/j.1872-034x.2008.00392.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 0.6] [Reference Citation Analysis]
174 Koziel MJ, Thio CL. Hepatitis B Virus and Hepatitis Delta Virus. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Elsevier; 2010. pp. 2059-86. [DOI: 10.1016/b978-0-443-06839-3.00146-6] [Cited by in Crossref: 5] [Article Influence: 0.5] [Reference Citation Analysis]
175 Ciancio A, Smedile A, Rizzetto M, Lagget M, Gerin J, Korba B. Identification of HBV DNA sequences that are predictive of response to lamivudine therapy. Hepatology. 2004;39:64-73. [PMID: 14752824 DOI: 10.1002/hep.20019] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
176 Semaine W, Johar M, Tyrrell DL, Kumar R, Agrawal B. Inhibition of hepatitis B virus (HBV) replication by pyrimidines bearing an acyclic moiety: effect on wild-type and mutant HBV. J Med Chem. 2006;49:2049-2054. [PMID: 15155222 DOI: 10.1021/jm058271d] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
177 Wai CT, Fontana RJ. Clinical significance of hepatitis B virus genotypes, variants, and mutants. Clin Liver Dis 2004;8:321-52, vi. [PMID: 15481343 DOI: 10.1016/j.cld.2004.02.006] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 2.8] [Reference Citation Analysis]
178 Stephan C, Berger A, Carlebach A, Lutz T, Bickel M, Klauke S, Staszewski S, Stuermer M. Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus. Journal of Antimicrobial Chemotherapy 2005;56:1087-93. [DOI: 10.1093/jac/dki396] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
179 Gauthier M, Bonnaud B, Arsac M, Lavocat F, Maisetti J, Kay A, Simon F, Zoulim F, Vernet G. Microarray for hepatitis B virus genotyping and detection of 994 mutations along the genome. J Clin Microbiol 2010;48:4207-15. [PMID: 20826635 DOI: 10.1128/JCM.00344-10] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
180 van der Eijk AA, Hansen BE, Niesters HG, Janssen HL, van de Ende M, Schalm SW, de Man RA. Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants. J Viral Hepat 2005;12:364-72. [PMID: 15985006 DOI: 10.1111/j.1365-2893.2005.00620.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
181 Levitsky J, Doucette K; the AST Infectious Diseases Community of Practice. Viral Hepatitis in Solid Organ Transplantation: Viral Hepatitis. American Journal of Transplantation 2013;13:147-68. [DOI: 10.1111/ajt.12108] [Cited by in Crossref: 56] [Cited by in F6Publishing: 46] [Article Influence: 7.0] [Reference Citation Analysis]
182 Shaw T, Bowden S, Locarnini S. Rescue therapy for drug resistant hepatitis B: another argument for combination chemotherapy? Gastroenterology. 2004;126:343-347. [PMID: 14699512 DOI: 10.1053/j.gastro.2003.11.022] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
183 Suzuki F, Akuta N, Suzuki Y, Sezaki H, Arase Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Ikeda K. Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants. J Med Virol. 2006;78:341-352. [PMID: 16419116 DOI: 10.1002/jmv.20546] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
184 Feld J, Locarnini S. Antiviral therapy for hepatitis B virus infections: new targets and technical challenges. J Clin Virol. 2002;25:267-283. [PMID: 12423691 DOI: 10.1016/s1386-6532(02)00107-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
185 Lee CH, Kim SO, Byun KS, Moon MS, Kim EO, Yeon JE, Yoo W, Hong SP. Predominance of hepatitis B virus YMDD mutants is prognostic of viral DNA breakthrough. Gastroenterology 2006;130:1144-52. [PMID: 16618409 DOI: 10.1053/j.gastro.2006.01.005] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
186 Coffin CS, Mulrooney-Cousins PM, Peters MG, van Marle G, Roberts JP, Michalak TI, Terrault NA. Molecular characterization of intrahepatic and extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive antiviral therapy. J Viral Hepat. 2011;18:415-423. [PMID: 20626626 DOI: 10.1111/j.1365-2893.2010.01321.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 43] [Article Influence: 5.2] [Reference Citation Analysis]
187 Vörös J, Urbanek A, Rautureau GJ, O'Connor M, Fisher HC, Ashcroft AE, Ferguson N. Large-scale production and structural and biophysical characterizations of the human hepatitis B virus polymerase. J Virol 2014;88:2584-99. [PMID: 24352439 DOI: 10.1128/JVI.02575-13] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
188 Zhang X, Chen X, Wei M, Zhang C, Xu T, Liu L, Xu Z. Potential resistant mutations within HBV reverse transcriptase sequences in nucleos(t)ide analogues-experienced patients with hepatitis B virus infection. Sci Rep 2019;9:8078. [PMID: 31147594 DOI: 10.1038/s41598-019-44604-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
189 Torresi J, Earnest-Silveira L, Civitico G, Walters TE, Lewin SR, Fyfe J, Locarnini SA, Manns M, Trautwein C, Bock TC. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the “fingers” subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. Virology. 2002;299:88-99. [PMID: 12167344 DOI: 10.1006/viro.2002.1448] [Cited by in Crossref: 96] [Cited by in F6Publishing: 89] [Article Influence: 5.1] [Reference Citation Analysis]
190 Schreibman IR, Schiff ER. Prevention and treatment of recurrent Hepatitis B after liver transplantation: the current role of nucleoside and nucleotide analogues. Ann Clin Microbiol Antimicrob 2006;5:8. [PMID: 16600049 DOI: 10.1186/1476-0711-5-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
191 Keeffe EB, Dieterich DT, Han SB, Jacobson IM, Martin P, Schiff ER, Tobias H. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2008 Update. Clinical Gastroenterology and Hepatology 2008;6:1315-41. [DOI: 10.1016/j.cgh.2008.08.021] [Cited by in Crossref: 315] [Cited by in F6Publishing: 280] [Article Influence: 24.2] [Reference Citation Analysis]
192 Delaney W, Bartholomeusz A, Locarnini SA. Evolving therapies for the treatment of chronic hepatitis B virus infection. Expert Opin Investig Drugs. 2002;11:169-187. [PMID: 11829711 DOI: 10.1517/13543784.11.2.169] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
193 Liu X, Schinazi RF. Hepatitis B virus resistance to lamivudine and its clinical implications. Antivir Chem Chemother. 2002;13:143-155. [PMID: 12448687 DOI: 10.1177/095632020201300301] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
194 Datta S, Chatterjee S, Veer V, Chakravarty R. Molecular biology of the hepatitis B virus for clinicians. J Clin Exp Hepatol. 2012;2:353-365. [PMID: 25755457 DOI: 10.1016/j.jceh.2012.10.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
195 Kim S, Lee J, Ryu WS. Four conserved cysteine residues of the hepatitis B virus polymerase are critical for RNA pregenome encapsidation. J Virol 2009;83:8032-40. [PMID: 19515776 DOI: 10.1128/JVI.00332-09] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
196 Bonacini M, Kurz A, Locarnini S, Ayres A, Gibbs C. Fulminant hepatitis B due to a lamivudine-resistant mutant of HBV in a patient coinfected with HIV. Gastroenterology. 2002;122:244-245. [PMID: 11806370 DOI: 10.1053/gast.2002.30901] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
197 Zhang KY, Imazeki F, Fukai K, Arai M, Kanda T, Mikata R, Yokosuka O. Analysis of the complete hepatitis B virus genome in patients with genotype C chronic hepatitis and hepatocellular carcinoma. Cancer Sci 2007;98:1921-9. [PMID: 17888035 DOI: 10.1111/j.1349-7006.2007.00609.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
198 Xunrong L, Yan AW, Liang R, Lau GK. Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy--pathogenesis and management. Rev Med Virol. 2001;11:287-299. [PMID: 11590667 DOI: 10.1002/rmv.322] [Cited by in Crossref: 82] [Cited by in F6Publishing: 74] [Article Influence: 4.1] [Reference Citation Analysis]
199 Sung JJ, Wong M, Bowden S, Liew C, Hui AY, Wong VW, Leung NW, Locarnini S, Chan HL. Intrahepatic Hepatitis B Virus Covalently Closed Circular DNA Can Be a Predictor of Sustained Response to Therapy. Gastroenterology 2005;128:1890-7. [DOI: 10.1053/j.gastro.2005.03.009] [Cited by in Crossref: 160] [Cited by in F6Publishing: 150] [Article Influence: 10.0] [Reference Citation Analysis]
200 Xu Z, Wu G, Li F, Bai J, Xing W, Zhang D, Zeng C. Positive selection signals of hepatitis B virus and their association with disease stages and viral genotypes. Infection, Genetics and Evolution 2013;19:176-87. [DOI: 10.1016/j.meegid.2013.07.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
201 Pas SD, Tran N, de Man RA, Burghoorn-Maas C, Vernet G, Niesters HG. Comparison of reverse hybridization, microarray, and sequence analysis for genotyping hepatitis B virus. J Clin Microbiol 2008;46:1268-73. [PMID: 18287321 DOI: 10.1128/JCM.01519-07] [Cited by in Crossref: 30] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
202 Matthews SJ. Entecavir for the treatment of chronic hepatitis B virus infection. Clin Ther. 2006;28:184-203. [PMID: 16678641 DOI: 10.1016/j.clinthera.2006.02.012] [Cited by in Crossref: 49] [Cited by in F6Publishing: 39] [Article Influence: 3.3] [Reference Citation Analysis]
203 Coffin CS, Lee SS. Treatment of HBeAg-positive patients with nucleos/tide analogues. Liver International 2009;29:116-24. [DOI: 10.1111/j.1478-3231.2008.01935.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
204 Martin CM, Welge JA, Shire NJ, Rouster SD, Shata MT, Sherman KE, Blackard JT. Genomic variability associated with the presence of occult hepatitis B virus in HIV co-infected individuals. J Viral Hepat. 2010;17:588-597. [PMID: 19889143 DOI: 10.1111/j.1365-2893.2009.01214.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
205 Deng L, Tang H. Hepatitis B virus drug resistance to current nucleos(t)ide analogs: Mechanisms and mutation sites. Hepatol Res. 2011;41:1017-1024. [PMID: 21917087 DOI: 10.1111/j.1872-034x.2011.00873.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
206 Cooley L, Ayres A, Bartholomeusz A, Lewin S, Crowe S, Mijch A, Locarnini S, Sasadeusz J. Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individuals. AIDS 2003;17:1649-57. [PMID: 12853747 DOI: 10.1097/00002030-200307250-00009] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 2.7] [Reference Citation Analysis]
207 Germer JJ, Charlton MR, Ishitani MB, Forehand CD, Patel R. Characterization of Hepatitis B Virus Surface Antigen and Polymerase Mutations in Liver Transplant Recipients Pre- and Post-Transplant: Hepatitis B Virus Mutation Analysis. American Journal of Transplantation 2003;3:743-53. [DOI: 10.1034/j.1600-6143.2003.00149.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
208 Wang YX, Wen YM, Nassal M. Carbonyl J acid derivatives block protein priming of hepadnaviral P protein and DNA-dependent DNA synthesis activity of hepadnaviral nucleocapsids. J Virol 2012;86:10079-92. [PMID: 22787212 DOI: 10.1128/JVI.00816-12] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
209 Chang TT, Gish RG, Hadziyannis SJ, Cianciara J, Rizzetto M, Schiff ER, Pastore G, Bacon BR, Poynard T, Joshi S. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology. 2005;129:1198-1209. [PMID: 16230074 DOI: 10.1053/j.gastro.2005.06.055] [Cited by in Crossref: 189] [Cited by in F6Publishing: 169] [Article Influence: 11.8] [Reference Citation Analysis]
210 Hann HW, Chae HB, Dunn SR. Tenofovir (TDF) has stronger antiviral effect than adefovir (ADV) against lamivudine (LAM)-resistant hepatitis B virus (HBV). Hepatol Int. 2008;2:244-249. [PMID: 19669311 DOI: 10.1007/s12072-008-9045-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 1.9] [Reference Citation Analysis]
211 Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, Brosgart C, Colledge D, Edwards R, Ayres A, Bartholomeusz A, Locarnini S. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003;125:292-7. [DOI: 10.1016/s0016-5085(03)00939-9] [Cited by in Crossref: 423] [Cited by in F6Publishing: 110] [Article Influence: 23.5] [Reference Citation Analysis]
212 Lin SM, Cheng J, Lu YY, Zhang SL, Yang Q, Chen TY, Liu M, Wang L. Screening and identification of interacting proteins with hepatitis B virus core protein in leukocytes and cloning of new gene C1. World J Gastroenterol 2006;12:1043-8. [PMID: 16534844 DOI: 10.3748/wjg.v12.i7.1043] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
213 Clark DN, Hu J. Unveiling the roles of HBV polymerase for new antiviral strategies. Future Virol. 2015;10:283-295. [PMID: 25893003 DOI: 10.2217/fvl.14.113] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
214 Ghozy S, Nam NH, Radwan I, Karimzadeh S, Tieu TM, Hashan MR, Abbas AS, Eid PS, Vuong NL, Khang NV, Elgabalawy E, Sayed AK, Hoa PTL, Huy NT. Therapeutic efficacy of hepatitis B virus vaccine in treatment of chronic HBV infections: A systematic review and meta-analysis. Rev Med Virol 2020;30:e2089. [PMID: 31811678 DOI: 10.1002/rmv.2089] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
215 Pawlotsky JM. Molecular diagnosis of viral hepatitis. Gastroenterology. 2002;122:1554-1568. [PMID: 12016423 DOI: 10.1053/gast.2002.33428] [Cited by in Crossref: 157] [Cited by in F6Publishing: 137] [Article Influence: 8.3] [Reference Citation Analysis]
216 Nishitsuji H, Yamamoto H, Shiina R, Harada K, Ujino S, Shimotohno K. Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle. J Vis Exp 2017. [PMID: 28190076 DOI: 10.3791/54849] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
217 Biswas A, Panigrahi R, Chandra PK, Banerjee A, Datta S, Pal M, Chakraborty S, Bhattacharya P, Chakrabarti S, Chakravarty R. Characterization of the occult hepatitis B virus variants circulating among the blood donors from eastern India. ScientificWorldJournal 2013;2013:212704. [PMID: 24302857 DOI: 10.1155/2013/212704] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
218 Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, Liaw YF, Mizokami M, Kuiken C;  Hepatitis B Virus Drug Resistance Working Group. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology. 2007;46:254-265. [PMID: 17596850 DOI: 10.1002/hep.21698] [Cited by in Crossref: 328] [Cited by in F6Publishing: 292] [Article Influence: 23.4] [Reference Citation Analysis]
219 Thibault V, Laperche S, Akhavan S, Servant-Delmas A, Belkhiri D, Roque-Afonso AM. Impact of hepatitis B virus genotypes and surface antigen variants on the performance of HBV real time PCR quantification. J Virol Methods 2009;159:265-70. [PMID: 19406163 DOI: 10.1016/j.jviromet.2009.04.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
220 Chin R, Locarnini S. Treatment of chronic hepatitis B: current challenges and future directions. Rev Med Virol. 2003;13:255-272. [PMID: 12820187 DOI: 10.1002/rmv.393] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.5] [Reference Citation Analysis]
221 Sun J, Wang Z, Ma S, Zeng G, Zhou Z, Luo K, Hou J. Clinical and virological characteristics of lamivudine resistance in chronic hepatitis B patients: A single center experience. J Med Virol 2005;75:391-8. [DOI: 10.1002/jmv.20281] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 1.1] [Reference Citation Analysis]
222 Litwin S, Toll E, Jilbert AR, Mason WS. The competing roles of virus replication and hepatocyte death rates in the emergence of drug-resistant mutants: theoretical considerations. J Clin Virol. 2005;34 Suppl 1:S96-S107. [PMID: 16461233 DOI: 10.1016/s1386-6532(05)80018-6] [Cited by in Crossref: 35] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
223 Michailidis E, Kirby KA, Hachiya A, Yoo W, Hong SP, Kim SO, Folk WR, Sarafianos SG. Antiviral therapies: focus on hepatitis B reverse transcriptase. Int J Biochem Cell Biol. 2012;44:1060-1071. [PMID: 22531713 DOI: 10.1016/j.biocel.2012.04.006] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
224 Wightman F, Walters T, Ayres A, Bowden S, Bartholomeusz A, Lau D, Locarnini S, Lewin SR. Comparison of sequence analysis and a novel discriminatory real-time PCR assay for detection and quantification of Lamivudine-resistant hepatitis B virus strains. J Clin Microbiol. 2004;42:3809-3812. [PMID: 15297535 DOI: 10.1128/jcm.42.8.3809-3812.2004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
225 van Bömmel F, de Man RA, Wedemeyer H, Deterding K, Petersen J, Buggisch P, Erhardt A, Hüppe D, Stein K, Trojan J. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology. 2010;51:73-80. [PMID: 19998272 DOI: 10.1002/hep.23246] [Cited by in Crossref: 241] [Cited by in F6Publishing: 231] [Article Influence: 21.9] [Reference Citation Analysis]
226 Ismail AM, Samuel P, Eapen CE, Kannangai R, Abraham P. Antiviral resistance mutations and genotype-associated amino acid substitutions in treatment-naïve hepatitis B virus-infected individuals from the Indian subcontinent. Intervirology 2012;55:36-44. [PMID: 21311172 DOI: 10.1159/000323521] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
227 van Bömmel F, Wünsche T, Schürmann D, Berg T. Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology 2002;36:507-8. [PMID: 12143063 DOI: 10.1053/jhep.2002.35328] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 2.7] [Reference Citation Analysis]
228 Tsai WL, Sun WC, Cheng JS. Chronic Hepatitis B with Spontaneous Severe Acute Exacerbation. Int J Mol Sci. 2015;16:28126-28145. [PMID: 26703566 DOI: 10.3390/ijms161226087] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
229 Tatti KM, Korba BE, Stang HL, Peek S, Gerin JL, Tennant BC, Schinazi RF. Mutations in the conserved woodchuck hepatitis virus polymerase FLLA and YMDD regions conferring resistance to lamivudine. Antiviral Res. 2002;55:141-150. [PMID: 12076758 DOI: 10.1016/s0166-3542(02)00019-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
230 Alvarado-Esquivel C, de la Ascensión Carrera-Gracia M, Conde-González CJ, Juárez-Figueroa L, Ruiz-Maya L, Aguilar-Benavides S, Torres-Valenzuela A, Sablon E. Genotypic resistance to lamivudine among hepatitis B virus isolates in Mexico. J Antimicrob Chemother. 2006;57:221-223. [PMID: 16373428 DOI: 10.1093/jac/dki457] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
231 Zhang HY, Liu LG, Ye CY, Chen CH, Hang SX, Zhu Z, Shen HY, Huang ZY, Chen WY, Xue Y. Evolution of drug-resistant mutations in HBV genomes in patients with treatment failure during the past seven years (2010-2016). Virus Genes. 2018;54:41-47. [PMID: 29119303 DOI: 10.1007/s11262-017-1518-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
232 Horiike N, Fazle Akbar SM, Michitaka K, Joukou K, Yamamoto K, Kojima N, Hiasa Y, Abe M, Onji M. In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B. J Clin Virol. 2005;32:156-161. [PMID: 15653419 DOI: 10.1016/j.jcv.2004.07.004] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 3.6] [Reference Citation Analysis]
233 Sheldon J, Rodès B, Zoulim F, Bartholomeusz A, Soriano V. Mutations affecting the replication capacity of the hepatitis B virus. J Viral Hepat 2006;13:427-34. [PMID: 16792535 DOI: 10.1111/j.1365-2893.2005.00713.x] [Cited by in Crossref: 90] [Cited by in F6Publishing: 80] [Article Influence: 6.0] [Reference Citation Analysis]
234 Cui C, Shi J, Hui L, Xi H, Zhuoma, Quni, Tsedan, Hu G. The dominant hepatitis B virus genotype identified in Tibet is a C/D hybrid. J Gen Virol 2002;83:2773-7. [PMID: 12388813 DOI: 10.1099/0022-1317-83-11-2773] [Cited by in Crossref: 76] [Cited by in F6Publishing: 74] [Article Influence: 4.0] [Reference Citation Analysis]
235 Beggel B, Neumann-Fraune M, Döring M, Lawyer G, Kaiser R, Verheyen J, Lengauer T. Genotyping hepatitis B virus dual infections using population-based sequence data. J Gen Virol 2012;93:1899-907. [PMID: 22694900 DOI: 10.1099/vir.0.043042-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
236 Li H, Song XF, Hu TT, Ren H, Hu P. A strong conservative tendency in HBV transcriptase (RT): a majority of natural RT mutations derived from the S gene. Liver Int 2016;36:963-70. [PMID: 26707356 DOI: 10.1111/liv.13051] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
237 Zhang JM, Yao X, Wang YX, Liu F, Ma ZM, Weng XH, Wen YM. High replicative full-length lamivudine-resistant hepatitis B virus isolated during acute exacerbations. J Med Virol. 2005;77:203-208. [PMID: 16121368 DOI: 10.1002/jmv.20453] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
238 Panigrahi R, Biswas A, De BK, Chakrabarti S, Chakravarty R. Characterization of antiviral resistance mutations among the Eastern Indian Hepatitis B virus infected population. Virol J. 2013;10:56. [PMID: 23409946 DOI: 10.1186/1743-422x-10-56] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
239 Delaney WE, Yang H, Westland CE, Das K, Arnold E, Gibbs CS, Miller MD, Xiong S. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol. 2003;77:11833-11841. [PMID: 14557667 DOI: 10.1128/jvi.77.21.11833-11841.2003] [Cited by in Crossref: 182] [Cited by in F6Publishing: 66] [Article Influence: 10.1] [Reference Citation Analysis]
240 Buti M. Current therapies for chronic hepatitis B. Annals of Hepatology 2003;2:108-12. [DOI: 10.1016/s1665-2681(19)32135-0] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
241 Bowden S, Bartholomeusz A, Locarnini S. Lamivudine resistant occult HBV: implications for public health? J Hepatol. 2003;38:526-528. [PMID: 12663248 DOI: 10.1016/s0168-8278(03)00079-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
242 Hu JL, Cui J, Guo JJ, Zhang WL, Cai XF, Yuan ZW, Li QL, Deng XY, Zeng AZ, Hu Y, Tang N, Huang AL. Phenotypic assay of a hepatitis B virus strain carrying an rtS246T variant using a new strategy. J Med Virol 2012;84:34-43. [PMID: 22052677 DOI: 10.1002/jmv.22260] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
243 Pondé RA. The underlying mechanisms for the "simultaneous HBsAg and anti-HBs serological profile". Eur J Clin Microbiol Infect Dis 2011;30:1325-40. [PMID: 21484253 DOI: 10.1007/s10096-011-1240-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
244 Faure E. Multiple sclerosis and hepatitis B vaccination: Could minute contamination of the vaccine by partial Hepatitis B virus polymerase play a role through molecular mimicry? Medical Hypotheses 2005;65:509-20. [DOI: 10.1016/j.mehy.2005.02.044] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
245 Chen RY, Bowden S, Desmond PV, Dean J, Locarnini SA. Effects of interferon alpha therapy on the catalytic domains of the polymerase gene and basal core promoter, precore and core regions of hepatitis B virus. J Gastroenterol Hepatol 2003;18:630-7. [PMID: 12753143 DOI: 10.1046/j.1440-1746.2003.03019.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
246 Coffin CS, Terrault NA. Management of hepatitis B in liver transplant recipients. J Viral Hepat. 2007;14 Suppl 1:37-44. [PMID: 17958641 DOI: 10.1111/j.1365-2893.2007.00916.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 34] [Article Influence: 3.5] [Reference Citation Analysis]
247 Felis-Giemza A, Olesińska M, Świerkocka K, Więsik-Szewczyk E, Haładyj E. Treatment of rheumatic diseases and hepatitis B virus coinfection. Rheumatol Int 2015;35:385-92. [PMID: 25549599 DOI: 10.1007/s00296-014-3195-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
248 Leung N. Lamivudine for chronic hepatitis B. Expert Rev Anti Infect Ther. 2004;2:173-180. [PMID: 15482184 DOI: 10.1586/14787210.2.2.173] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
249 Wang YW, Shan X, Huang Y, Deng H, Huang WX, Zhang DZ, Chen J, Tang N, Shan YL, Guo JJ, Huang A. A novel baseline hepatitis B virus sequencing-based strategy for predicting adefovir antiviral response. Infect Genet Evol 2015;33:269-76. [PMID: 25983054 DOI: 10.1016/j.meegid.2015.05.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
250 Lindström A, Odeberg J, Albert J. Pyrosequencing for detection of lamivudine-resistant hepatitis B virus. J Clin Microbiol. 2004;42:4788-4795. [PMID: 15472342 DOI: 10.1128/jcm.42.10.4788-4795.2004] [Cited by in Crossref: 55] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
251 Pai SB, Bozdayi AM, Pai RB, Beker T, Sarioglu M, Turkyilmaz AR, Grier J, Yurdaydin C, Schinazi RF. Emergence of a novel mutation in the FLLA region of hepatitis B virus during lamivudine therapy. Antimicrob Agents Chemother 2005;49:2618-24. [PMID: 15980328 DOI: 10.1128/AAC.49.7.2618-2624.2005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
252 Kramvis A, Kew M, François G. Hepatitis B virus genotypes. Vaccine 2005;23:2409-23. [DOI: 10.1016/j.vaccine.2004.10.045] [Cited by in Crossref: 241] [Cited by in F6Publishing: 235] [Article Influence: 15.1] [Reference Citation Analysis]
253 Locarnini S, Mason WS. Cellular and virological mechanisms of HBV drug resistance. J Hepatol. 2006;44:422-431. [PMID: 16364492 DOI: 10.1016/j.jhep.2005.11.036] [Cited by in Crossref: 119] [Cited by in F6Publishing: 108] [Article Influence: 7.4] [Reference Citation Analysis]